Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Cetrorelix acetate
Cetrorelix · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Day 1 protocol | EXPERIMENTAL | - |
| Day 7 protocol | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cetrorelix acetate | DRUG | Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period \[S0\]) until r-hCG day (at least 2 follicles \>=17 mm) |
| Recombinant Human Choriogonadotropin (r-hCG) | DRUG | The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day |
| Recombinant human follicle stimulating hormone (r-hFSH) | DRUG | Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period \[S1\]) until r-hCG day |
Inclusion Criteria: * Female subjects with PCO or Polycystic ovary syndrome (PCOS) according to the revised 2003 Rotterdam Consensus * Female subjects suitable for IVF/ICSI, undergoing first or second attempt * 18-35 years old, Body Mass Index (BMI) less than or equal to 32, non-smoking at least fr...
Cetrorelix is used for Polycystic Ovarian Syndrome, specifically in women undergoing assisted reproductive technology. It is a small molecule being developed by Merck & Company, Inc. (MRK) and is currently in Phase 3 clinical development.
Cetrorelix targets the gonadotropin-releasing hormone receptor, acting as an antagonist to suppress premature luteinizing hormone surges during controlled ovarian stimulation. This mechanism helps manage Polycystic Ovarian Syndrome in assisted reproductive technology.
Cetrorelix is developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker MRK. The drug is also known as Cetrorelix acetate.
Cetrorelix is in Phase 3 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is being studied for Polycystic Ovarian Syndrome.
Cetrorelix has one completed Phase 3 trial, NCT01185704, which analyzed two therapeutic approaches with Cetrotide in Polycystic Ovarian women in assisted reproductive technology. The trial enrolled 136 female participants aged 18 years and older in France.
Yes, Cetrorelix is also known as Cetrorelix acetate. Both names refer to the same drug, which is being developed by Merck & Company, Inc. for Polycystic Ovarian Syndrome.